Vericel Corp (VCEL)
30.26
+0.32
(+1.07%)
USD |
NASDAQ |
Mar 21, 11:15
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 1.433B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -13.54% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 8.677 |
| Price to Book Value | 7.454 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.00 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 73.97% |
News
Headline
Wire
Time (ET)
Globe Newswire
02/28 08:30
MT Newswires
02/27 10:38
MT Newswires
02/23 10:39
MT Newswires
02/23 07:56
Yahoo
02/23 07:55
MT Newswires
01/31 09:37
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 05/04/2023* | 08:30 EST | Earnings Call | Q1 2023 | -- | -- | -- | |
| 05/04/2023* | -- | Results | Q1 2023 | -- | -0.15 | -- | |
| 02/23/2023 | -- | Results | Q4 2022 | 0.13 | 0.05 | 178.6% | |
| 02/23/2023 | 08:30 EST | Earnings Call | Q4 2022 | -- | -- | -- | |
| 11/09/2022 | -- | Results | Q3 2022 | -0.14 | -0.12 | -20.00% | |
| 11/09/2022 | 08:30 EST | Earnings Call | Q3 2022 | -- | -- | -- | |
| 08/03/2022 | 08:30 EST | Earnings Call | Q2 2022 | -- | -- | -- | |
| 08/03/2022 | -- | Results | Q2 2022 | -0.19 | -0.12 | -58.33% |
*Estimated Date/Time
Earnings
Profile
Edit
| Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company, specialized in advanced therapies for sports medicine and severe burn care markets. It markets two cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane) and Epicel (cultured epidermal autografts). The company operates in one reportable segment: the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases. |
| URL | https://www.vcel.com |
| Investor Relations URL | https://investors.vcel.com/ |
| HQ State/Province | Massachusetts |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Growth |
| Next Earnings Release | May. 04, 2023 (est.) |
| Last Earnings Release | Feb. 23, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | -- |
| Yield (TTM) | 0% |
| Forward Yield | -- |
| Payout Ratio | 0.00% |
| Cash Payout Ratio | 0.00% |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk
Total Returns Comparison
Annual Total Returns Versus Peers
As of March 20, 2023.
Fundamentals
| Revenue (TTM) | 164.36M |
| Total Expenses (TTM) | 181.42M |
| Net Income (TTM) | -16.71M |
| Total Assets (Quarterly) | 273.00M |
| Total Liabilities (Quarterly) | 80.73M |
| Shareholders Equity (Quarterly) | 192.27M |
| Cash from Operations (TTM) | 17.69M |
| Cash from Investing (TTM) | -36.21M |
| Cash from Financing (TTM) | 1.045M |
Ratings
Profile
Edit
| Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company, specialized in advanced therapies for sports medicine and severe burn care markets. It markets two cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane) and Epicel (cultured epidermal autografts). The company operates in one reportable segment: the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases. |
| URL | https://www.vcel.com |
| Investor Relations URL | https://investors.vcel.com/ |
| HQ State/Province | Massachusetts |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Growth |
| Next Earnings Release | May. 04, 2023 (est.) |
| Last Earnings Release | Feb. 23, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Nasdaq | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| VCEL Tweets |